<DOC>
	<DOCNO>NCT02848183</DOCNO>
	<brief_summary>The purpose study optimize therapy accord know risk factor treatment response pediatric acute myeloid leukemia ( AML )</brief_summary>
	<brief_title>Optimal Treatment Strategy Based Pediatric AML</brief_title>
	<detailed_description>I . Risk group assessment Favorable prognosis group : Low risk feature + Good response Intermediate prognosis group : 1 . Low risk feature + Delayed response-1 2 . Standard risk feature + Good response 3 . Standard risk feature + Delayed response-1 Poor prognosis group : 1 . Any high risk feature irrespective treatment response 2 . Any delayed response-2 irrespective risk feature 3 . Any refractory state irrespective risk feature 4 . Any early relapse II . Chemotherapy Induction-1 : Cytarabine + idarubicin Induction-2 : High dose ( HD ) cytarabine + mitoxantrone Consolidation-1 : Cytarabine + idarubicin Consolidation-2 : HD cytarabine + etoposide Consolidation-3 : HD cytarabine + mitoxantrone Consolidation-4 : HD cytarabine + etoposide III . Allogeneic hematopoietic stem cell transplantation ( HSCT ) Favorable prognosis group : chemotherapy Intermediate prognosis group : chemotherapy HSCT reduce intensity conditioning Poor prognosis group : HSCT myeloablative conditioning</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients newly diagnose de novo AML Patients recurrent cytogenetic abnormality AML even though bone marrow blast percent low 20 % Acute promyelocytic leukemia Down syndrome AML Therapyrelated AML AML develop myelodysplastic syndrome marrow failure syndrome Isolated myeloid sarcoma without bone marrow involvement Patients undergo chemotherapy schedule due serious complication diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>